Business Context and Reporting Period
Company: Smith & Nephew plc (LSE: SN, NYSE: SNN)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: December 8, 2025
Context: Announcement of the new "RISE" strategy, 2028 financial targets, and updated guidance for 2025 and 2026. The RISE strategy succeeds the 12-Point Plan transformation and focuses on reaching more patients, innovation, scaling strategic investments, and efficient execution.
Key Financial Metrics and Targets
2025 Full Year Guidance (Updated)
- Underlying Revenue Growth: Around 5% (approx. 5.8% at prevailing exchange rates).
- Trading Profit Margin: At least 19.5% (within guided range of 19.0%–20.0%; 2024 was 18.1%).
- Free Cash Flow: Upgraded to around $800 million (previously guided as >$600 million).
- Post-Tax ROIC: Expected to be >9% (excluding portfolio rationalization impact; 2024 was 7.4%).
- One-Time Provision: Estimated $200 million non-cash inventory provision due to portfolio rationalization.
2026 Full Year Provisional Guidance
- Underlying Revenue Growth: Around 6% (approx. 5.8% at prevailing exchange rates).
- Profit Growth: Expected to outpace revenue growth due to operating leverage.
- Free Cash Flow: Around $800 million.
- Post-Tax ROIC: Expected to increase to >10%.
2028 Financial Targets
- Revenue CAGR: 6–7% underlying compound annual growth rate.
- Trading Profit CAGR: 9–10%.
- Free Cash Flow: More than $1 billion.
- Post-Tax ROIC: 12–13%.
Material Changes and Strategic Actions
- Strategy Shift: Transition from the 12-Point Plan to the "RISE" strategy to accelerate growth and returns.
- Portfolio Rationalization: Identified opportunities to simplify the product range, aiming to reduce gross inventory by approximately $500 million over time.
- Capital Efficiency: The $200 million non-cash provision in 2025 is intended to reduce capital requirements and complexity, particularly in the Orthopaedics segment under the new "Ortho 360" operating model.
- Margin Expansion: Trading profit margin guidance for 2025 has been raised to a minimum of 19.5%, reflecting operational efficiencies.
Outlook, Risks, and Management Commentary
Management Commentary: CEO Deepak Nath stated that the RISE strategy is an "ambitious but achievable" roadmap. The company expects Sports Medicine, Advanced Wound Management, and ENT to drive above-market growth, while Orthopaedics will return to market-level growth with margin expansion.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks cited include geopolitical conflicts (Europe/Middle East), economic conditions affecting healthcare payers, regulatory approvals, reimbursement decisions, supply chain disruptions, cybersecurity, and foreign exchange volatility.
Unusual Items: The $200 million non-cash inventory provision is a significant one-time charge in 2025 related to portfolio rationalization, which will impact reported earnings but not cash flow.
Investor Verification Checklist
- Verify the execution of the $200 million non-cash inventory provision and its specific impact on 2025 reported earnings versus cash flow.
- Monitor the actual underlying revenue growth rates in 2025 and 2026 to confirm the acceleration from 5% to 6%.
- Track the progress of the "Ortho 360" operating model and the reduction of gross inventory by the targeted $500 million.
- Assess the realization of the 2028 ROIC target (12–13%) relative to the company's Weighted Average Cost of Capital (WACC).
- Review the 2025 full-year results scheduled for March 2, 2026, to confirm the provisional 2026 guidance.